MX347463B - Terapia de combinación de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf. - Google Patents

Terapia de combinación de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf.

Info

Publication number
MX347463B
MX347463B MX2013001839A MX2013001839A MX347463B MX 347463 B MX347463 B MX 347463B MX 2013001839 A MX2013001839 A MX 2013001839A MX 2013001839 A MX2013001839 A MX 2013001839A MX 347463 B MX347463 B MX 347463B
Authority
MX
Mexico
Prior art keywords
antibody
afucosylated
combination therapy
vegf
vegf antibody
Prior art date
Application number
MX2013001839A
Other languages
English (en)
Other versions
MX2013001839A (es
Inventor
Christian Klein
Frank Herting
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of MX2013001839A publication Critical patent/MX2013001839A/es
Publication of MX347463B publication Critical patent/MX347463B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a la terapia de combinación de un anticuerpo anti-CD20 afucosilado con un anticuerpo anti-VEGF para el tratamiento del cáncer, especialmente a la terapia de combinación de los cánceres que expresan CD20 con un anticuerpo B-Lyl afucosilado humanizado y un anticuerpo anti-VEGF.
MX2013001839A 2010-08-17 2011-08-16 Terapia de combinación de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf. MX347463B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10173108 2010-08-17
PCT/EP2011/064097 WO2012022747A1 (en) 2010-08-17 2011-08-16 Combination therapy of an afucosylated cd20 antibody with an anti-vegf antibody

Publications (2)

Publication Number Publication Date
MX2013001839A MX2013001839A (es) 2013-03-07
MX347463B true MX347463B (es) 2017-04-26

Family

ID=42731850

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013001839A MX347463B (es) 2010-08-17 2011-08-16 Terapia de combinación de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf.

Country Status (12)

Country Link
US (3) US20130183290A1 (es)
EP (1) EP2605793A1 (es)
JP (2) JP5778279B2 (es)
KR (1) KR101522113B1 (es)
CN (1) CN103096926B (es)
AR (1) AR082693A1 (es)
BR (1) BR112013002441A2 (es)
CA (1) CA2807243C (es)
MX (1) MX347463B (es)
RU (1) RU2615459C2 (es)
TW (1) TW201208703A (es)
WO (1) WO2012022747A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9296820B2 (en) 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
BR112015027474A8 (pt) * 2013-05-02 2018-01-23 Hoffmann La Roche anticorpo, composição, método de tratamento do paciente que sofre de câncer e uso de um anticorpo.
ME03675B (me) 2013-07-05 2020-10-20 Genmab As Humanizovana ili himerna anтi-cd3 antiтela
WO2018106945A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
WO2018183929A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
EP3883635A1 (en) 2018-11-19 2021-09-29 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
TW202337494A (zh) 2021-11-16 2023-10-01 美商建南德克公司 用莫蘇妥珠單抗治療全身性紅斑狼瘡（ｓｌｅ）之方法及組成物

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
AU687727B2 (en) 1992-10-28 1998-03-05 Genentech Inc. Vascular endothelial cell growth factor antagonists
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
KR100816621B1 (ko) 1997-04-07 2008-03-24 제넨테크, 인크. 항-ｖｅｇｆ 항체
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
PT971959E (pt) 1997-04-07 2006-05-31 Genentech Inc Anticorpos humanizados e metodos para formar anticorpos humanizados
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
KR20010071271A (ko) 1998-05-15 2001-07-28 존 비. 랜디스 방사선 및 성장 인자 수용체 티로신 키나아제 억제제에의한 사람 종양의 치료법
WO2000035956A1 (fr) 1998-12-16 2000-06-22 Kyowa Hakko Kogyo Co., Ltd. Anticorps monoclonal anti-vegf humain
CA2704600C (en) 1999-04-09 2016-10-25 Kyowa Kirin Co., Ltd. A method for producing antibodies with increased adcc activity
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
CA2463879C (en) 2001-10-25 2012-12-04 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
BRPI0315295C1 (pt) 2002-10-17 2021-05-25 Genmab As anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
EP2248892B1 (en) 2003-01-22 2015-04-22 Roche Glycart AG Fusion constructs and use of same to produce antibodies with increased FC receptor binding affinity and effector function
UA101945C2 (uk) 2003-05-30 2013-05-27 Дженентек, Инк. Лікування злоякісного новоутворення за допомогою бевацизумабу
EP1648511A1 (en) 2003-07-29 2006-04-26 Morphotek, Inc. Antibodies and methods for generating genetically altered antibodies with enhanced effector function
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
AU2004266159A1 (en) 2003-08-22 2005-03-03 Biogen Idec Ma Inc. Improved antibodies having altered effector function and methods for making the same
AU2004273791A1 (en) 2003-09-05 2005-03-31 Genentech, Inc. Antibodies with altered effector functions
US9296820B2 (en) 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
US8008443B2 (en) 2005-04-26 2011-08-30 Medimmune, Llc Modulation of antibody effector function by hinge domain engineering
WO2006114700A2 (en) 2005-04-26 2006-11-02 Bioren, Inc. Method of producing human igg antibodies with enhanced effector functions
JP2008541758A (ja) * 2005-06-02 2008-11-27 アストラゼネカ エービー Ｃｄ２０に対する抗体およびその使用
CA2615636A1 (en) * 2005-08-12 2007-02-22 Regeneron Pharmaceuticals, Inc. Treatment of diseases by subcutaneous administration of a vegf antagonist
AU2006290433B2 (en) 2005-08-26 2012-06-07 Roche Glycart Ag Modified antigen binding molecules with altered cell signaling activity
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
AU2008295140A1 (en) * 2007-09-05 2009-03-12 F. Hoffmann-La Roche Ag Combination therapy with type I and type II anti-CD20 antibodies
US20090110688A1 (en) * 2007-10-24 2009-04-30 Georg Fertig Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor

Also Published As

Publication number Publication date
US20140322200A1 (en) 2014-10-30
WO2012022747A1 (en) 2012-02-23
MX2013001839A (es) 2013-03-07
JP2013535511A (ja) 2013-09-12
TW201208703A (en) 2012-03-01
CN103096926B (zh) 2016-02-10
RU2615459C2 (ru) 2017-04-04
HK1180228A1 (zh) 2013-10-18
US20160017050A1 (en) 2016-01-21
RU2013109172A (ru) 2014-09-27
CN103096926A (zh) 2013-05-08
CA2807243C (en) 2018-09-11
AR082693A1 (es) 2012-12-26
JP2015187130A (ja) 2015-10-29
KR20130055660A (ko) 2013-05-28
US20130183290A1 (en) 2013-07-18
BR112013002441A2 (pt) 2016-05-24
JP5778279B2 (ja) 2015-09-16
CA2807243A1 (en) 2012-02-23
EP2605793A1 (en) 2013-06-26
KR101522113B1 (ko) 2015-05-20

Similar Documents

Publication Publication Date Title
MX2012001782A (es) Terapia de combinacion de un anticuerpo cd20 afucosilado y bendamustina.
MX2013006739A (es) Terapia combinada de anticuerpo cd20 afucosilado con inhibidor de mdm2.
MY178726A (en) Combination therapy of an afucosylated cd20 antibody with a btk inhibitor
MX347463B (es) Terapia de combinación de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf.
MX2012001783A (es) Terapia combinatoria de un anticuerpo anti-cd20 afucosilado con fludarabina y/o mitoxantrona.
MY181960A (en) Combination therapy of an afucosylated cd20 antibody with a cd79b antibody-drug conjugate
TN2015000396A1 (en) Antibody drug conjugates
MX2015002947A (es) Terapia de combinacion de un anticuerpo ant-cd20 tipo ii con un inhibidor blc-2 selectivo.
MX2012012118A (es) Terapia de combinacion de un anticuerpo cd20 afucosilado con un inhibidor mtor.
AU2011338480A8 (en) Humanized antibodies to LIV-1 and use of same to treat cancer
NZ702748A (en) Cd33 antibodies and use of same to treat cancer
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
MX2010002406A (es) Terapia de combinacion con anticuerpos anti-cd20 de tipo i y de tipo ii.
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
PH12014501541A1 (en) Combination therapy of antibodies against human csf-1r and uses thereof
AU2011338383A8 (en) Treatment of HER2-positive cancer with paclitaxel and trastuzumab-MCC-DM1
NZ711867A (en) Combination therapy of an afucosylated cd20 antibody with a cd22 antibody-drug conjugate
NZ736727A (en) Combination therapy of an anti cd20 antibody with a bcl-2 inhibitor and a mdm2 inhibitor
PH12014501543A1 (en) Combination therapy for the treatment of ovarian cancer
AU2012371260A8 (en) Predicitive biomarker for cancer treatment with ADCC enhanced antibodies
WO2012106473A8 (en) Dosing for treatment with anti-egfl7 antibodies

Legal Events

Date Code Title Description
FG Grant or registration